Bioventus Competitors

SEMrush (NASDAQ:SEMR) and Bioventus (NYSE:BVS) are both -- companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Earnings and Valuation

This table compares SEMrush and Bioventus' top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for SEMrush and Bioventus, as provided by MarketBeat.

SEMrush presently has a consensus price target of $20.0833, suggesting a potential upside of 10.23%. Bioventus has a consensus price target of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than SEMrush.

Profitability

This table compares SEMrush and Bioventus' net margins, return on equity and return on assets.

Summary

Bioventus beats SEMrush on 3 of the 3 factors compared between the two stocks.

The Duckhorn Portfolio (NYSE:NAPA) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares The Duckhorn Portfolio and Bioventus' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for The Duckhorn Portfolio and Bioventus, as provided by MarketBeat.com.

The Duckhorn Portfolio presently has a consensus target price of $20.7778, suggesting a potential upside of 22.22%. Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than The Duckhorn Portfolio.

Profitability

This table compares The Duckhorn Portfolio and Bioventus' net margins, return on equity and return on assets.

Summary

Bioventus beats The Duckhorn Portfolio on 2 of the 3 factors compared between the two stocks.

ThredUp (NASDAQ:TDUP) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares ThredUp and Bioventus' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for ThredUp and Bioventus, as provided by MarketBeat.com.

ThredUp presently has a consensus target price of $20.8571, suggesting a potential upside of 14.79%. Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than ThredUp.

Profitability

This table compares ThredUp and Bioventus' net margins, return on equity and return on assets.

Summary

Bioventus beats ThredUp on 2 of the 3 factors compared between the two stocks.

PLBY Group (NASDAQ:PLBY) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares PLBY Group and Bioventus' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a breakdown of recent ratings and target prices for PLBY Group and Bioventus, as provided by MarketBeat.com.

PLBY Group presently has a consensus target price of $45.6667, suggesting a potential downside of 2.67%. Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' higher probable upside, analysts plainly believe Bioventus is more favorable than PLBY Group.

Profitability

This table compares PLBY Group and Bioventus' net margins, return on equity and return on assets.

Summary

Bioventus beats PLBY Group on 2 of the 2 factors compared between the two stocks.

Design Therapeutics (NASDAQ:DSGN) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Earnings & Valuation

This table compares Design Therapeutics and Bioventus' top-line revenue, earnings per share and valuation.

Profitability

This table compares Design Therapeutics and Bioventus' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Design Therapeutics and Bioventus, as provided by MarketBeat.com.

Design Therapeutics presently has a consensus target price of $35.3333, suggesting a potential upside of 53.69%. Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Design Therapeutics' higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Bioventus.

Summary

Bioventus beats Design Therapeutics on 2 of the 3 factors compared between the two stocks.

Thoma Bravo Advantage (NYSE:TBA) and Bioventus (NYSE:BVS) are both small-cap -- companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Valuation & Earnings

This table compares Thoma Bravo Advantage and Bioventus' top-line revenue, earnings per share and valuation.

Profitability

This table compares Thoma Bravo Advantage and Bioventus' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and price targets for Thoma Bravo Advantage and Bioventus, as provided by MarketBeat.

Bioventus has a consensus target price of $19.50, suggesting a potential upside of 23.03%. Given Bioventus' higher probable upside, analysts clearly believe Bioventus is more favorable than Thoma Bravo Advantage.

Summary

Bioventus beats Thoma Bravo Advantage on 2 of the 2 factors compared between the two stocks.